297 related articles for article (PubMed ID: 33780283)
41. Identification of Somatic Gene Signatures in Circulating Cell-Free DNA Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning Platform.
Lin E; Hahn AW; Nussenzveig RH; Wesolowski S; Sayegh N; Maughan BL; McFarland T; Rathi N; Sirohi D; Sonpavde G; Swami U; Kohli M; Rich T; Sartor O; Yandell M; Agarwal N
Oncologist; 2021 Sep; 26(9):751-760. PubMed ID: 34157173
[TBL] [Abstract][Full Text] [Related]
42. Lineage plasticity in cancer: a shared pathway of therapeutic resistance.
Quintanal-Villalonga Á; Chan JM; Yu HA; Pe'er D; Sawyers CL; Sen T; Rudin CM
Nat Rev Clin Oncol; 2020 Jun; 17(6):360-371. PubMed ID: 32152485
[TBL] [Abstract][Full Text] [Related]
43. Genomic and clinical characterization of pulmonary-only metastatic prostate cancer: A unique molecular subtype.
Shenderov E; Isaacsson Velho P; Awan AH; Wang H; Mirkheshti N; Lotan TL; Carducci MA; Pardoll DM; Eisenberger MA; Antonarakis ES
Prostate; 2019 Sep; 79(13):1572-1579. PubMed ID: 31389628
[TBL] [Abstract][Full Text] [Related]
44. Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary.
Hofmann MR; Hussain M; Dehm SM; Beltran H; Wyatt AW; Halabi S; Sweeney C; Scher HI; Ryan CJ; Feng FY; Attard G; Klein E; Miyahira AK; Soule HR; Sharifi N
Urology; 2021 Sep; 155():165-171. PubMed ID: 33373705
[TBL] [Abstract][Full Text] [Related]
45. p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer.
Maughan BL; Guedes LB; Boucher K; Rajoria G; Liu Z; Klimek S; Zoino R; Antonarakis ES; Lotan TL
Prostate Cancer Prostatic Dis; 2018 Jun; 21(2):260-268. PubMed ID: 29302046
[TBL] [Abstract][Full Text] [Related]
46. Transient Sox9 Expression Facilitates Resistance to Androgen-Targeted Therapy in Prostate Cancer.
Nouri M; Massah S; Caradec J; Lubik AA; Li N; Truong S; Lee AR; Fazli L; Ramnarine VR; Lovnicki JM; Moore J; Wang M; Foo J; Gleave ME; Hollier BG; Nelson C; Collins C; Dong X; Buttyan R
Clin Cancer Res; 2020 Apr; 26(7):1678-1689. PubMed ID: 31919137
[TBL] [Abstract][Full Text] [Related]
47. A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterations.
Kobayashi H; Kosaka T; Nakamura K; Shojo K; Hongo H; Mikami S; Nishihara H; Oya M
BMC Med Genomics; 2021 Oct; 14(1):245. PubMed ID: 34627261
[TBL] [Abstract][Full Text] [Related]
48. Loss of Androgen-Regulated MicroRNA 1 Activates SRC and Promotes Prostate Cancer Bone Metastasis.
Liu YN; Yin J; Barrett B; Sheppard-Tillman H; Li D; Casey OM; Fang L; Hynes PG; Ameri AH; Kelly K
Mol Cell Biol; 2015 Jun; 35(11):1940-51. PubMed ID: 25802280
[TBL] [Abstract][Full Text] [Related]
49. Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy.
Van Allen EM; Foye A; Wagle N; Kim W; Carter SL; McKenna A; Simko JP; Garraway LA; Febbo PG
Prostate Cancer Prostatic Dis; 2014 Mar; 17(1):23-7. PubMed ID: 24366412
[TBL] [Abstract][Full Text] [Related]
50. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
[TBL] [Abstract][Full Text] [Related]
51. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
[TBL] [Abstract][Full Text] [Related]
52. Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer.
van der Doelen MJ; Isaacsson Velho P; Slootbeek PHJ; Pamidimarri Naga S; Bormann M; van Helvert S; Kroeze LI; van Oort IM; Gerritsen WR; Antonarakis ES; Mehra N
Eur J Cancer; 2020 Sep; 136():16-24. PubMed ID: 32634759
[TBL] [Abstract][Full Text] [Related]
53. Exceptional response to cyclophosphamide and dexamethasone in a patient with metastatic castrate-resistant prostate cancer and RB1 mutation.
Dohogne B; Arif-Tiwari H; Bracamonte E; Babiker HM
Anticancer Drugs; 2021 Mar; 32(3):337-343. PubMed ID: 33534414
[TBL] [Abstract][Full Text] [Related]
54. AR-regulated TWEAK-FN14 pathway promotes prostate cancer bone metastasis.
Yin J; Liu YN; Tillman H; Barrett B; Hewitt S; Ylaya K; Fang L; Lake R; Corey E; Morrissey C; Vessella R; Kelly K
Cancer Res; 2014 Aug; 74(16):4306-17. PubMed ID: 24970477
[TBL] [Abstract][Full Text] [Related]
55. Differential expression of androgen receptor variants in hormone-sensitive prostate cancer xenografts, castration-resistant sublines, and patient specimens according to the treatment sequence.
Honda M; Kimura T; Kamata Y; Tashiro K; Kimura S; Koike Y; Sato S; Yorozu T; Furusato B; Takahashi H; Kiyota H; Egawa S
Prostate; 2019 Jun; 79(9):1043-1052. PubMed ID: 30998834
[TBL] [Abstract][Full Text] [Related]
56. Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer.
Slootbeek PHJ; Duizer ML; van der Doelen MJ; Kloots ISH; Kuppen MCP; Westgeest HM; Uyl-de Groot CA; Pamidimarri Naga S; Ligtenberg MJL; van Oort IM; Gerritsen WR; Schalken JA; Kroeze LI; Bloemendal HJ; Mehra N
Int J Cancer; 2021 Jan; 148(2):385-395. PubMed ID: 32965028
[TBL] [Abstract][Full Text] [Related]
57. Do the expressions of epithelial-mesenchymal transition proteins, periostin, integrin-α4 and fibronectin correlate with clinico-pathological features and prognosis of metastatic castration-resistant prostate cancer?
Konac E; Kiliccioglu I; Sogutdelen E; Dikmen AU; Albayrak G; Bilen CY
Exp Biol Med (Maywood); 2017 Dec; 242(18):1795-1801. PubMed ID: 28836852
[TBL] [Abstract][Full Text] [Related]
58. Gene expression analysis of bone metastasis and circulating tumor cells from metastatic castrate-resistant prostate cancer patients.
Cho WJ; Oliveira DS; Najy AJ; Mainetti LE; Aoun HD; Cher ML; Heath E; Kim HR; Bonfil RD
J Transl Med; 2016 Mar; 14():72. PubMed ID: 26975354
[TBL] [Abstract][Full Text] [Related]
59. Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a
Abida W; Patnaik A; Campbell D; Shapiro J; Bryce AH; McDermott R; Sautois B; Vogelzang NJ; Bambury RM; Voog E; Zhang J; Piulats JM; Ryan CJ; Merseburger AS; Daugaard G; Heidenreich A; Fizazi K; Higano CS; Krieger LE; Sternberg CN; Watkins SP; Despain D; Simmons AD; Loehr A; Dowson M; Golsorkhi T; Chowdhury S;
J Clin Oncol; 2020 Nov; 38(32):3763-3772. PubMed ID: 32795228
[TBL] [Abstract][Full Text] [Related]
60. Expression of STAT3 in Prostate Cancer Metastases.
Don-Doncow N; Marginean F; Coleman I; Nelson PS; Ehrnström R; Krzyzanowska A; Morrissey C; Hellsten R; Bjartell A
Eur Urol; 2017 Mar; 71(3):313-316. PubMed ID: 27344294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
